|
|
Office Locations:
|
10751 Falls Road, Suite 300
Baltimore, MD 21093
Phone: 410-494-4230
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Red Abbey Venture Partners was founded in 2004 and has invested in 14 privately-held and 9 publicly-traded life science companies. Red Abbey Venture Partners is the second generation of a life sciences investment program that Frank A. Bonsal, Jr. and Philip Goelet, PhD began in 1997 with an investment in RiboTargets Holdings. The Partnership's primary investment objective is to generate superior, risk-adjusted returns by investing in high-quality life sciences companies that are developing novel therapeutics and other products based on distinctive technologies. The firm expects to capitalize on the advances in molecular biology, drug discovery and medical treatment that have permanently changed the treatment and management of disease. Red Abbey has a select group of family offices and individual investors who have committed $50 million to its fund.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
